Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

Dipartimento di Medicina Interna and Centro di Ricerca, Trasferimento ed alta Formazione DenoTHE, University of Florence, Viale Morgagni 85, I-50134, Florence, Italy.
Trends in Molecular Medicine (Impact Factor: 10.11). 03/2008; 14(2):72-81. DOI: 10.1016/j.molmed.2007.12.003
Source: PubMed

ABSTRACT Non-alcoholic steatohepatitis (NASH), a cause of cirrhosis and hepatocellular carcinoma, is characterized by fatty infiltration of the liver, inflammation, hepatocellular damage and fibrosis. Progress has been made in understanding the molecular and cellular mechanisms implicated in the pathogenesis of this condition, therefore, we here review recent developments regarding the basic mechanisms of NASH development. Accumulation of triglycerides in the hepatocytes is the result of increased inflow of free fatty acids and de novo lipogenesis. Steatosis leads to lipotoxicity, which causes apoptosis, necrosis, generation of oxidative stress and inflammation. The resulting chronic injury activates a fibrogenic response that leads eventually to end-stage liver disease. A better understanding of these mechanisms is crucial for the design of novel diagnostic and therapeutic strategies.

Download full-text


Available from: Gianluca Tell, Apr 22, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fatty acids have traditionally been described as artery clogging species that is detrimental to overall health. The most prevalent fatty acid is palmitic acid (PA), a sixteen carbon chain fatty acid that is ubiquitous in biological systems. PA is prevalent in most eukaryotic cell membranes and in the mitochondria derived from the Krebs’ cycle utilizing acetyl-coenzyme A as its’ precursor. PA is found in a variety of plants with a high amounts in coconut oil. Many cosmetics, shampoos, and commercialized beauty products contain PA providing structure and substance to the gel or reagent. An emerging field of study is the esterified form of PA or methyl palmitate, as it is involved in biological signaling in the central nervous system. More specifically, methyl palmitate or palmitic acid methyl ester can cause arterial vasodilation and is thought to be involved in neurotransmission, as well as modulate vascular tonicity in cerebral circulation. Methyl palmitate has also been implicated as a neuroprotective agent in both models of focal and global cerebral ischemia; however, the exact mechanism(s) are still unknown. We will focus on the known pharmacology, biochemistry, and clinical implications of PA and other related fatty acids (i.e. Non-esterified v. esterified fatty acids) commonly found in daily diets. Additionally, cellular target(s) of PA will be discussed as it relates to improvement of disease states, synthesis, and possible health implications/benefits of methyl palmitate in biological systems.
    Palmitic Acid: Occurrence, Biochemistry and Health Effects, Edited by Lucas F. Porto, 01/2014; Nova Science Pub Inc., ISBN: 1633215199
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for advanced liver disease, type 2 diabetes (T2DM), and cardiovascular diseases. The prevalence of NAFLD in the general population is around 30 %, but it is up to three times higher in those with T2DM. Among people with obesity and T2DM, the NAFLD epidemic also is worsening. Therefore, it is important to identify early metabolic alterations and to prevent these diseases and their progression. In this review, we analyze the pathophysiologic mechanisms leading to NAFLD, particularly, those common to T2DM, such as liver and muscle insulin resistance. However, it is mainly adipose tissue insulin resistance that results in increased hepatic de novo lipogenesis, inflammation, and lipotoxicity. Although genetics predispose to NAFLD, an unhealthy lifestyle, including high-fat/high-sugar diets and low physical activity, increases the risk. In addition, alterations in gut microbiota and environmental chemical agents, acting as endocrine disruptors, may play a role.
    Current Diabetes Reports 06/2015; 15(6):607. DOI:10.1007/s11892-015-0607-4 · 3.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Morphine is metabolized in humans to the pharmacologically active morphine-6-glucuronide (M6G) and inactive morphine-3-glucuronide (M3G). The hepatobiliary disposition of both metabolites relies upon Mrp3 and Mrp2, located on the sinusoidal and canalicular membrane, respectively. Nonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease, alters xenobiotic metabolizing enzyme and transporter function. The purpose of this study was to determine whether NASH contributes to the large inter-individual variability and postoperative adverse events associated with morphine therapy. Male Sprague-Dawley rats were fed a control diet or a methionine and choline deficient diet to induce NASH. Radiolabeled morphine (2.5mg/kg, 30μCi/kg) was administered intravenously, and plasma and bile (0-150 or 0-240 min), liver and kidney, and cumulative urine were analyzed for morphine and M3G. The antinociceptive response to M6G (5mg/kg) was assessed (0-12 h) following direct intraperitoneal administration since rats do not produce M6G. NASH caused a net decrease in morphine concentrations in the bile and plasma and a net increase in the M3G/morphine plasma AUC ratio, consistent with upregulation of Ugt2b1. Despite increased systemic exposure to M3G, NASH resulted in decreased biliary excretion and hepatic accumulation of M3G. This shift towards systemic retention is consistent with the mislocalization of canalicular Mrp2 and increased expression of sinusoidal Mrp3 in NASH and may correlate to increased antinociception by M6G. Increased metabolism and altered transporter regulation in NASH provide a mechanistic basis for inter-individual variability in morphine disposition that may lead to opioid-related toxicity. The American Society for Pharmacology and Experimental Therapeutics.
    Journal of Pharmacology and Experimental Therapeutics 12/2014; 352(3). DOI:10.1124/jpet.114.220764 · 3.86 Impact Factor